Donnatal Tablets
Drug Labeling and Warnings
Drug Details [pdf]
DONNATAL- phenobarbital, hyoscyamine sulfate, atropine sulfate, scopolamine hydrobromide tablet
McKesson Corporation dba RX Pak
Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.
----------
Donnatal Tablets
Description
Each Donnatal® Tablet contains:
Phenobarbital, USP....................................... 16.2 mg
Hyoscyamine Sulfate, USP...................... 0.1037 mg
Atropine Sulfate, USP ...............................0.0194 mg
Scopolamine Hydrobromide, USP ...........0.0065 mg
INACTIVE INGREDIENTS: Anhydrous Lactose, Calcium Stearate, Colloidal
Silicon Dioxide, Corn Starch, and Microcrystalline Cellulose.
INACTIVE INGREDIENTS
Anhydrous Lactose, Calcium Stearate, Colloidal Silicon Dioxide, Corn Starch, and Microcrystalline Cellulose
CLINICAL PHARMACOLOGY
This drug combination provides natural belladonna alkaloids in a specific, fixed ratio combined with phenobarbital to
provide peripheral anticholinergic/antispasmodic action and mild sedation.
INDICATIONS AND USAGE
Based on a review of this drug by the National Academy of Sciences-National Research Council and/or other
information, FDA has classified the following indications as “possibly” effective:
For use as adjunctive therapy in the treatment of irritable bowel syndrome (irritable colon, spastic colon, mucous colitis)
and acute enterocolitis.
May also be useful as adjunctive therapy in the treatment of duodenal ulcer. IT HAS NOT BEEN SHOWN
CONCLUSIVELY WHETHER ANTICHOLINERGIC/ANTISPASMODIC DRUGS AID IN THE HEALING OF A
DUODENAL ULCER, DECREASE THE RATE OF RECURRENCES OR PREVENT COMPLICATIONS.
CONTRAINDICATIONS
Glaucoma, obstructive uropathy (for example, bladder neck obstruction due to prostatic hypertrophy); obstructive
disease of the gastrointestinal tract (as in achalasia, pyloroduodenal stenosis, etc.); paralytic ileus, intestinal atony of
the elderly or debilitated patient; unstable cardiovascular status in acute hemorrhage; severe ulcerative colitis
especially if complicated by toxic mega-colon; myasthenia gravis; hiatal hernia associated with reflux esophagitis.
Donnatal® is contraindicated in patients with known hypersensitivity to any of the ingredients. Phenobarbital is
contraindicated in acute intermittent porphyria and in those patients in whom phenobarbital produces restlessness
and/or excitement.
WARNINGS
In the presence of a high environmental temperature, heat prostration can occur with belladonna alkaloids (fever and
heatstroke due to decreased sweating).
Diarrhea may be an early symptom of incomplete intestinal obstruction, especially in patients with ileostomy or
colostomy. In this instance, treatment with this drug would be inappropriate and possibly harmful.
Donnatal® may produce drowsiness or blurred vision. The patient should be warned, should these occur, not to
engage in activities requiring mental alertness, such as operating a motor vehicle or other machinery, and not to
perform hazardous work.
Phenobarbital may decrease the effect of anticoagulants, and necessitate larger doses of the anticoagulant for optimal
effect. When the phenobarbital is discontinued, the dose of the anticoagulant may have to be decreased.
Phenobarbital may be habit forming and should not be administered to individuals known to be addiction prone or to
those with a history of physical and/or psychological dependence upon drugs.
Since barbiturates are metabolized in the liver, they should be used with caution and initial doses should be small in
patients with hepatic dysfunction.
PRECAUTIONS
Use with caution in patients with: autonomic neuropathy, hepatic or renal disease, hyperthyroidism, coronary heart
disease, congestive heart failure, cardiac arrhythmias, tachycardia, and hypertension.
Belladonna alkaloids may produce a delay in gastric emptying (antral stasis) which would complicate the management
of gastric ulcer.
Do not rely on the use of the drug in the presence of complication of biliary tract disease.
Theoretically, with overdosage, a curare-like action may occur.
CARCINOGENESIS, MUTAGENESIS, IMPAIRMENT OF FERTILITY
Long-term studies in animals have not been performed to evaluate carcinogenic potential.
PREGNANCY
PREGNANCY CATEGORY C
Animal reproduction studies have not been conducted with Donnatal®. It is not known whether Donnatal® can cause
fetal harm when administered to a pregnant woman or can affect reproduction capacity. Donnatal® should be given to
a pregnant woman only if clearly needed.
NURSING MOTHERS
It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution
should be exercised when Donnatal® is administered to a nursing woman.
ADVERSE REACTIONS
Adverse reactions may include xerostomia; urinary hesitancy and retention; blurred vision; tachycardia; palpitation;
mydriasis; cycloplegia; increased ocular tension; loss of taste sense; headache; nervousness; drowsiness; weakness;
dizziness; insomnia; nausea; vomiting; impotence; suppression of lactation; constipation; bloated feeling;
musculoskeletal pain; severe allergic reaction or drug idiosyncrasies, including anaphylaxis, urticaria and other dermal
manifestations; and decreased sweating. Acquired hypersensitivity to barbituates consists chiefly in allergic reactions
that occur especially in persons who tend to have asthma, urticaria, angiodema and similar conditions. Hypersensitivity
reactions in this category include localized swelling, particularly of the eyelids, cheeks, or lips, and erythematous
dermatitis. Rarely, exfoliative dermatitis (e.g. Stevens-Johnson syndrome and toxic epidermal necrolysis) may be
caused by phenobarbital and can prove fatal. The skin eruption may be associated with fever, delirium, and marked
degenerative changes in the liver and other parenchymatous organs. In a few cases, megaloblastic anemia has been
associated with the chronic use of phenobarbital. Elderly patients may react with symptoms of excitement, agitation,
drowsiness, and other untoward manifestations to even small doses of the drug. Phenobarbital may produce
excitement in some patients, rather than a sedative effect. In patients habituated to barbiturates, abrupt withdrawal
may produce delirium or convulsions.
DOSAGE AND ADMINISTRATION
The dosage of Donnatal® should be adjusted to the needs of the dividual patient to assure symptomatic control with a
minimum of adverse effects.
Donnatal® Tablets. Adults: One or two Donnatal® tablets three or four times a day according to condition and severity
of symptoms.
OVERDOSAGE
The signs and symptoms of overdose are headache, nausea, vomiting, blurred vision, dilated pupils, hot and dry skin,
dizziness, dryness of the mouth, difficulty in swallowing, and CNS stimulation. Treatment should consist of gastric
lavage, emetics, and activated charcoal. If indicated, parenteral cholinergic agents such as physostigmine or
bethanechol chloride, should be used.
How Supplied
Donnatal® Tablets are supplied as: White, D-shaped tablets debossed “D” on one side and “Donnatal” on the other
side.
Bottles of 100 tablets.
Bottles of 1000 tablets.
AVOID FREEZING
Store at 20-25°C (68-77°F) [See USP Controlled Room Temperature].
Protect from light and moisture.
Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure. Use safety closures
when dispensing this product unless otherwise directed by a physician or requested by purchaser.
Also available: Donnatal Extentabs® Tablets, the only extended release formulation, in bottles of 100 and 500 tablets.
Donnatal® Elixir, a purple colored, grape flavored liquid, in 4 fl oz (118 mL) and 1 pint (473 mL) bottles.
| DONNATAL
phenobarbital, hyoscyamine sulfate, atropine sulfate, scopolamine hydrobromide tablet |
||||||||||||||||||
|
||||||||||||||||||
|
||||||||||||||||||
|
||||||||||||||||||
|
||||||||||||||||||
|
||||||||||||||||||
|
||||||||||||||||||
| Labeler - McKesson Corporation dba RX Pak (025183281) |
| Establishment | |||
| Name | Address | ID/FEI | Business Operations |
|---|---|---|---|
| McKesson Corporation dba RX Pak | 025183281 | RELABEL(65084-123) , REPACK(65084-123) | |